BioPharmSignal logoBioPharmSignal

Biotech News

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

Virax Biolabs (VRAX)Virax BiolabsCompany update

VRAX (VRAX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is vrax.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VRAXVirax Biolabs2025-11-03 13:29 EST

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

VRAXVirax Biolabs2025-08-26 11:30 EST

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

BIAFbioAffinity Technologies, Inc.2026-07-27 12:08 EST

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

BDSXBiodesix2026-05-11 13:17 EST

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

View all latest news

Virax Biolabs

Virax Biolabs is a diagnostics company focused on immune profiling and infectious-disease testing. Its business is centered on molecular and laboratory diagnostics rather than therapeutics.

Recent company news

VRAXVirax Biolabs2026-07-16 11:30 EST

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

VRAXVirax Biolabs2026-07-10 20:05 EST

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

VRAXVirax Biolabs2026-07-09 17:35 EST

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

VRAXVirax Biolabs2026-07-09 11:30 EST

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

VRAXVirax Biolabs2026-06-24 13:00 EST

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

Stock data

Close
2.77 USD
Market cap
1.61M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States